Drug Search Results
More Filters [+]

Cicletanine

Alternative Names: cicletanine
Latest Update: 2021-09-05
Latest Update Note: Clinical Trial Update

Product Description

Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cicletanine)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | France

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cicletanine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Hyponatremia|Hypertension|Hypokalemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CHAMP

P2

Unknown status

Hypertension|Hyponatremia|Hypokalemia

2024-06-01

24%

2008-007455-26

P2

Terminated

Hypertension, Pulmonary

2012-01-05

GS-US-235-0101

P2

Terminated

Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension

2011-10-01

Recent News Events

Date

Type

Title